IL158071A0 - Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer - Google Patents

Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Info

Publication number
IL158071A0
IL158071A0 IL15807102A IL15807102A IL158071A0 IL 158071 A0 IL158071 A0 IL 158071A0 IL 15807102 A IL15807102 A IL 15807102A IL 15807102 A IL15807102 A IL 15807102A IL 158071 A0 IL158071 A0 IL 158071A0
Authority
IL
Israel
Prior art keywords
health
related quality
progression
patients
disease
Prior art date
Application number
IL15807102A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL158071A0 publication Critical patent/IL158071A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL15807102A 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer IL158071A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08
PCT/US2002/011397 WO2002085351A1 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Publications (1)

Publication Number Publication Date
IL158071A0 true IL158071A0 (en) 2004-03-28

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15807102A IL158071A0 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Country Status (10)

Country Link
EP (1) EP1379238A1 (de)
JP (1) JP2005503339A (de)
CN (1) CN1514727A (de)
AR (1) AR033465A1 (de)
BR (1) BR0205970A (de)
CA (1) CA2442591A1 (de)
IL (1) IL158071A0 (de)
MX (1) MXPA03009277A (de)
PE (1) PE20021032A1 (de)
WO (1) WO2002085351A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
JP2009537535A (ja) * 2006-05-15 2009-10-29 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド エンドセリンアンタゴニストの投与を含む睡眠時無呼吸を治療するための方法および組成物
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003740A2 (de) * 1997-08-04 2000-05-31 Abbott Laboratories Pyrrolidin-3-carbonsäure derivate und ihre verwendung als endothelin-antagonisten

Also Published As

Publication number Publication date
PE20021032A1 (es) 2002-11-12
CA2442591A1 (en) 2002-10-31
BR0205970A (pt) 2003-09-30
EP1379238A1 (de) 2004-01-14
WO2002085351A1 (en) 2002-10-31
CN1514727A (zh) 2004-07-21
MXPA03009277A (es) 2004-03-10
AR033465A1 (es) 2003-12-17
JP2005503339A (ja) 2005-02-03

Similar Documents

Publication Publication Date Title
AU2002243495A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
AU2002352820A1 (en) Calibration of tissue densities in computerized tomography
AU2004207813A8 (en) Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
AU2002339844A1 (en) Screening and therapeutic methods for promoting wakefulness and sleep
AU2001264559A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
IL158071A0 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002356898A8 (en) Gene amplification and overexpression in cancer
EP1436323A4 (de) Kristallstruktur von baff und deren verwendung bei der entwicklung von arzneimitteln
IL169369A0 (en) Thienopyridazinones and their use in modulation of autoimmune disease
EP1385879A4 (de) Diagnose und therapie von krebs der fortpflanzungsorgane
AU2002257139A1 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
AU2002340251A8 (en) Use of mx gtpases in the prognosis and treatment of cancer
AU2001233955A1 (en) Diagnosis and treatment of bipolar affective disorder
PT1617876E (pt) Tório-227 para utilização em radioterapia na doença do tecido mole
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003301160A8 (en) Amplified cancer target genes useful in diagnosis and therapeutic screening
AU2002316688A1 (en) Lipophilin complexes for use in cancer diagnosis and therapy
AU2002310470A1 (en) Use of ribonuclease l in diagnosis of cancer
AU2002251286A1 (en) Diagnosis and treatment of cancer:ii
ZA200309828B (en) Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis